Studying a new form of olaparib for BRCA-mutated ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 19 and 74 years old.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer with a BRCA gene mutation (inherited or in the tumor).
- You have been taking olaparib (Lynparza) at a stable dose for at least 3 months.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have severe allergies to the study drug ingredients or serious stomach/intestinal problems that could affect drug absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.